Standard practice

Phase 3Small molecule

NNICHD Neonatal Research Network

Standard practice is one of 57 small molecule programs targeting Respiratory Failure. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory FailureActive, not recruiting

Breast CancerActive, not recruiting

Respiratory FailurePhase 3

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Trodelvy

Gilead

Preclinical

37 2

Prolia

Amgen

Preclinical

14 3

Standard practice

NNICHD Neonatal Research Network

Phase 3

1 4

Megace

Bristol-Myers Squibb

Preclinical

4 5

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 6

Chirocaine

PPurdue Pharma LP

Preclinical

1 7

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

3 8

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

1 9

Systemic Treatment

TTaproot Health

Preclinical

1 10

Tetracycline Hydrochloride

EEuropean Organisation for Research and Treatment of Cancer - EORTC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Respiratory Failure1 trial

Early Inhaled Nitric Oxide for Respiratory Failure in Newborns

Terminated·NNICHD Neonatal Research Network·Phase 3·NCT00005773·302 enrolled

Low Birth Weight1 trial

Early Surfactant to Reduce Use of Mechanical Breathing in Low Birth Weight Infants

Terminated·NNICHD Neonatal Research Network·Phase 3·NCT00005774·61 enrolled

Breast Cancer1 trial

Efficacy and Safety of Estracyt® in Metastatic Breast Cancer

Withdrawn·—·Phase 2·NCT02853071

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Standard practice. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Standard practice compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Standard practice. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NICHD Neonatal Research Network company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNICHD Neonatal Research Network

Standard practice

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Respiratory Failure1 trial

Low Birth Weight1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News